Table 2.

Most common drug-related adverse events in the safety analysis set

Event	Arm A Nivolumab (N = 15)		Arm B Capecitabine (N = 15)		Arm C Nivolumab and Capecitabine (N = 15)
	All Grades	Grade 3	All Grades	Grade 3	All Grades	Grade 3
	Number of patients (%)
Endocrine disorders: Hypothyroidism	3 (20)	0	0	0	2 (13.3)	0
Gastrointestinal disorders
Abdominal pain	0	0	2 (13.3)	0	5 (33.3)	1 (6.7)
Diarrhea	1 (6.7)	0	7 (46.7)	0	7 (46.7)	2 (13.3)
Nausea	0	0	4 (26.7)	0	2 (13.3)	0
Oral mucositis	0	0	3 (20)	2 (13.3)	3 (20)	0
General disorders: fatigue	6 (40)	0	5 (33.3)	0	4 (26.7)	2 (13.3)
Musculoskeletal and connective tissue disorders: arthralgia	5 (33.3)	0	1 (6.7)	0	0	0
Nervous system disorders: Peripheral sensory neuropathy	0	0	3 (20)	0	4 (26.7)	0
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia syndrome	0	0	7 (46.7)	0	5 (33.4)	0
Skin and subcutaneous tissue disorders	0	0	1 (6.7)	0	4 (26.7)	0